What Xaira Therapeutics does
Xaira Therapeutics is an AI-native biotechnology company founded to “re-engineer” drug discovery and development using end-to-end AI methods, expansive biological data generation, and therapeutic product development. The company’s strategy is built around a closed loop in which data-generation (including large-scale single-cell perturbation experiments) feeds model training, and the resulting models are then used to drive target and therapeutic design as well as clinical/precision-medicine decisions.
More
Xaira publicly emphasizes model-and-data milestones in the “virtual cell” line of work. Its virtual-cell system is associated with the X-Atlas perturb-seq resources (including Orion and Pisces) and the X-Cell virtual cell model. In March 2026, Xaira announced X-Cell as its first virtual cell model trained on X-Atlas/Pisces, reporting that it generalizes to unseen biological experiments. In June 2025, Xaira announced X-Atlas/Orion as a large publicly released perturb-seq atlas generated using its Fix-Cryopreserve-ScRNAseq (FiCS) Perturb-seq platform; that release included details on the dataset size and a method for detecting dose-dependent genetic effects. On the leadership side, Xaira has expanded its C-suite and executive leadership over time, including the promotions and appointments announced in July 2026 for roles spanning translational science/early clinical development and AI-enabled discovery leadership. Business model (as publicly described): Xaira does not sell software as a standalone product; instead, it develops therapeutics and builds proprietary AI platforms and data-generation capabilities to support an internal pipeline, using partnerships and public scientific releases to accelerate model/data progress. The company’s press materials consistently describe it as an “integrated biotechnology company” and as building platforms to advance a pipeline of novel medicines.